Genmab
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 240
- Registration Number
- NCT06018129
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Expanded Access Program for Epcoritamab
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Genmab
- Registration Number
- NCT05733650
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 180
- Registration Number
- NCT05660967
- Locations
- 🇺🇸
UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States
🇦🇹Kepler Universitätsklinikum, Linz, Austria
🇦🇹LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 26
- Registration Number
- NCT05586321
- Locations
- 🇬🇪
ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia
🇲🇩ARENSIA Exploratory Medicine Phase I Unit, Chisinau, Moldova, Republic of
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 900
- Registration Number
- NCT05578976
- Locations
- 🇺🇸
Orlando Health Cancer Institute /ID# 232626, Orlando, Florida, United States
🇺🇸University of Illinois at Chicago /ID# 226889, Chicago, Illinois, United States
🇺🇸University of Maryland, Baltimore /ID# 225421, Baltimore, Maryland, United States
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 88
- Registration Number
- NCT05491317
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷Centre Leon Berard, Lyon, France
🇫🇷Institut Gustave Roussy, Villejuif, France
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 184
- Registration Number
- NCT05451810
- Locations
- 🇺🇸
Our Lady Of The Lake Regional Medical Center /ID# 255008, Baton Rouge, Louisiana, United States
🇺🇸Dartmouth-Hitchcock Medical Center - 1 Medical Center Drive /ID# 245003, Lebanon, New Hampshire, United States
🇺🇸OhioHealth Arthur G.H. Bing, MD Cancer Center /ID# 260803, Columbus, Ohio, United States
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Genmab
- Target Recruit Count
- 31
- Registration Number
- NCT05435339
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 500
- Registration Number
- NCT05409066
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences /ID# 227198, Little Rock, Arkansas, United States
🇺🇸Beverly Hills Cancer Center /ID# 231535, Beverly Hills, California, United States
🇺🇸Valkyrie Clinical Trials /ID# 268502, Los Angeles, California, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
🇺🇸Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States